Tech Stocks
Cannabis Stocks
Index Funds
International
Short
Stock Picks

Username or Email Address

Password

Remember Me

Lost Password?

Inside the push to weaken Washington’s toughest financial watchdog

Scared to spend your retirement money? Here’s one way to get over the fear of running out.

It’s ‘unavoidable’: Apple says it will be forced to raise prices due to the AI boom

Did Warsh and Vance just open the door to higher inflation?

Historic NBA Finals ratings and Fox’s $22 billion Roku deal show live sports are key to winning the streaming wars

Retail investors have been buying more SpaceX shares than all of the ‘Magnificent Seven’ combined

OutPerformDaily

Tech Stocks
Cannabis Stocks
Index Funds
International
Short
Stock Picks

Tech Stocks
Cannabis Stocks
Index Funds
International
Short
Stock Picks

JPM26: Eli Lilly reportedly eyes €15bn takeover of Abivax

January 12, 2026

Abivax’s lead asset is obefazimod, an anti-inflammatory drug that has produced positive Phase III results.

You may also like

Amazon vs. Costco: Which Stock Is a Better Buy?

Amazon vs. Costco: Which Stock Is a Better Buy?

February 28, 2026

Cross Staff Loads Up on 289,000 Shares of AKRE

Cross Staff Loads Up on 289,000 Shares of AKRE

February 28, 2026

AMD Ties Meta And Nutanix Deals To Long Term AI Growth Narrative

AMD Ties Meta And Nutanix Deals To Long Term AI Growth Narrative

February 28, 2026

Indices by TradingView

Inside the push to weaken Washington’s toughest financial watchdog

June 17, 2026

Scared to spend your retirement money? Here’s one way to get over the fear of running out.

June 17, 2026

It’s ‘unavoidable’: Apple says it will be forced to raise prices due to the AI boom

June 17, 2026

Did Warsh and Vance just open the door to higher inflation?

June 17, 2026

Historic NBA Finals ratings and Fox’s $22 billion Roku deal show live sports are key to winning the streaming wars

June 17, 2026

Categories

3rdPartyFeeds
Cannabis Stocks
Index Funds
International
News
Short
Stock Picks
Tech Stocks
Uncategorized

Indices by TradingView

While subscribers receive the benefit of Outperformdaily opinions, none of the information contained therein constitutes a recommendation from Outperformdaily that any particular security, portfolio of securities, transaction, option, or investment strategy is suitable for any specific person. You further understand that we will not advise you personally concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter. To the extent any of the information contained in Outperformdaily may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person. Outperformdaily’s past results are not necessarily indicative of future performance. All investments are subject to loss. Our employees and writters typically personally invest in all recommendations, but they are not obligated too. Our employees and writters are prohibited from taking an opposite position from which they write about.